Manuel Sepulveda
16Patents
3h-index
25Co-inventors
52Inventor score
Filing activity: Jun 23, 2016 → Apr 28, 2022
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US10611823B2 | CD137 binding fibronectin type III domains | Chemistry; Metallurgy | 9 | Active |
| US10626165B2 | CD8a-binding fibronectin type III domains | Physics | 9 | Active |
| US10597438B2 | PD-L1 binding fibronectin type III domains | Chemistry; Metallurgy | 9 | Active |
| US11009509B2 | Anti-VISTA antibodies and fragments | Physics | 2 | Active |
| US11345739B2 | CD137 binding fibronectin type III domains | Chemistry; Metallurgy | 1 | Active |
| US11299534B2 | CD8A-binding fibronectin type III domains | Physics | 1 | Active |
| US12258385B2 | CD137 binding fibronectin type III domains | Chemistry; Metallurgy | 0 | Active |
| US11932680B2 | CD8A-binding fibronectin type III domains | Physics | 0 | Active |
| US12275766B2 | Neoantigen peptide mimics | Chemistry; Metallurgy | 0 | Active |
| US11447539B2 | PD-L1 binding fibronectin type III domains | Chemistry; Metallurgy | 0 | Active |
| US11793843B2 | Prostate neoantigens and their uses | Chemistry; Metallurgy | 0 | Active |
| US12188938B2 | Anti-VISTA antibodies and fragments | Physics | 0 | Active |
| US12018289B2 | Vaccines based on mutant CALR and JAK2 and their uses | Chemistry; Metallurgy | 0 | Active |
| US11945881B2 | Neoantigens expressed in ovarian cancer and their uses | Chemistry; Metallurgy | 0 | Active |
| US12295997B2 | Prostate neoantigens and their uses | Chemistry; Metallurgy | 0 | Active |
| US12264197B2 | Anti-Vβ17/anti-CD123 bispecific antibodies | Chemistry; Metallurgy | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.